Science and Research

Analysis of Driving Factors of Willingness to Use and Willingness to Pay for Existing Pharmacological Smoking Cessation Aids Among Young and Middle-Aged Adults in Germany

BACKGROUND: Smoking cessation is a challenging task with a high risk of relapse. Depending on the choice of medication and duration of therapy, the costs of using a smoking cessation aid can be high. Additionally, these costs are not covered by health insurance in Germany. Information on willingness to use (WTU) and willingness to pay (WTP) for smoking cessation aids is valuable for developing different smoking cessation strategies. OBJECTIVES: The study analyses WTU and WTP for three pharmacological smoking cessation aids (nicotine replacement therapy (NRT), bupropion and varenicline) among young and middle-aged adults in Germany and attempts to determine their major driving factors. METHODS: Two cross-sectional internet-based surveys of smokers over 18 years of age were conducted in 2014 and 2015 in Germany. Respondents were asked about smoking-related issues and WTU and WTP for each therapy. The contingent valuation method with payment cards was used to measure WTP. Descriptive statistics, logistical regression and accelerated failure-time regression models were performed. RESULTS: The total sample size is 505. Half of the respondents are willing to use NRT and one-third are willing to use bupropion and/or varenicline. WTU induces positive WTP; however, the magnitude of WTP is beneath the market price. WTU significantly increases with a higher addiction level and if smokers have previously heard about the therapy. CONCLUSION: This study indicates different points to be considered for policy development. Promotion information and improving awareness about medication aids might increase WTU, and development of monetary incentives for young smokers could create a better chance for successful smoking cessation.

  • Aumann, I.; Treskova, M.; Hagemann, N.; von der Schulenburg, J. M.

Keywords

  • Adult
  • Aged
  • Bupropion/*economics/therapeutic use
  • Cost-Benefit Analysis
  • Cross-Sectional Studies
  • Dopamine Uptake Inhibitors/economics/therapeutic use
  • Female
  • Financing, Personal/*economics/statistics & numerical data
  • Germany
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Nicotinic Agonists/economics/therapeutic use
  • Patient Acceptance of Health Care/*statistics & numerical data
  • Smoking Cessation/*economics/methods
  • Tobacco Use Cessation Products/adverse effects/*economics
  • Varenicline/*economics/therapeutic use
  • Young Adult
Publication details
DOI: 10.1007/s40258-016-0239-0
Journal: Applied health economics and health policy
Pages: 441-452 
Number: 4
Work Type: Original
Location: BREATH
Disease Area: COPD
Partner / Member: LUH
Access-Number: 27021824
See publication on PubMed

DZL Engagements

chevron-down